Click here to close now.

SYS-CON MEDIA Authors: Elizabeth White, AppDynamics Blog, Ian Goldsmith, Ed Featherston, Pat Romanski

News Feed Item

Parkinson's Disease: World Drug Industry and Market 2014-2024

NEW YORK, March 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Parkinson's Disease: World Drug Industry and Market 2014-2024

http://www.reportlinker.com/p02041935/Parkinsons-Disease-World-Drug-Industry-and-Market-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

Treating Parkinson's - how you find business trends, R&D, and revenue forecasts

See the future of Parkinson's drugs. For those treatments you can get new sales predictions, also exploring research and development. You unlock that CNS medical industry. And you assess its results, trends, technologies, therapies, and opportunities.

Visiongain's report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. You stay ahead in data, then, finding commercial prospects. And you hear about gains for companies, doctors, and patients, also benefiting your influence.

So read on to investigate those medicines and see what their future could be worth.

Sales predictions to 2024 and other analyses show you commercial prospects

Besides forecasting revenues to 2024, our study gives you recent results, growth rates, and market shares. There you find original analysis, with business outlooks and developments (R&D). Also you get 68 tables, 47 charts, and interviews with two companies.

There you discover the most lucrative opportunities for treating that central nervous system (CNS) disorder. You find where the money lies, exploring existing and potential sales.

Knowledge to help your work on that degenerative disorder

Ever found business data hard to find? Instead see how our report helps your research, analyses, and decisions for treatment of Parkinson's disease (PD). Save time too, and stay ahead. Also benefit your authority through better understanding the present and future.

Avoid missing out. And the following sections explain what you get in that new investigation.

Forecasting of that world market and its segments - you explore possibilities

What're the secrets of that industry's progress? Where lies potential in alleviating symptoms and treating PD? Discover in our report overall world revenue to 2024 for those central nervous system (CNS) medicines.

Also find individual revenue predictions to 2024 for five therapeutic submarkets at world level:• Dopaminergic agents• Dopamine receptor agonists• COMT inhibitors• MAO inhibitors• Treatments with other modes of action (grouped).

There you assess outlooks for sales growth, seeing where you can gain.

Like to know what happens next? You explore competition and rising sales for products, including biological drugs (biologics). You get feel for that sector and its potential.

So discover the sales possibilities there. See, too, how patients benefit. And you find top products' potentials.

Predictions of revenues for leading Parkinson's drugs

Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for three leading products:

• Comtan and Stalevo

• Azilect

• Neupro.

There you find products and years with highest predicted revenues and growth. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and sales potentials. Discover where you could profit.

Our work also divides its overall predictions into geographical regions.

Healthcare in leading national markets - what outlooks for those medical sales?

In developed and developing countries, opportunities for selling products treating Parkinson's disease will improve from 2014 to 2024. See where and how, finding commercial potentials of therapeutic agents for that neurodegenerative disorder.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:• United States (US)• Japan• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)• BRIC nations - Brazil, Russia, India, and China.

There you find countries with highest revenues, demand, and potential sales growth. Our work explains. You assess needs and demands for that specialist medicine.

Explore, too, how that biomedical and biopharma technology benefits developers, producers, marketers, and sellers tackling that neurological disease.

Also, what events change that market? Our work shows you, discussing trends and needs.

Events and forces for developing, producing, marketing, and selling PD medicines

Our report shows you issues and events affecting that biomedical and pharma segment from 2014, including these:

• R&D for Parkinson's (idiopathic or primary parkinsonism, hypokinetic rigid syndrome/HRS, or paralysis agitans), including stem cells and gene therapy

• Levodopa therapy, its reformulations, and patient expiry - rising competition

• Demographic trends worldwide affecting treatment needs and demand for PD drugs

• Economic changes stimulating sales of those medical agents

• Neuroprotective medicines (neuroprotection) giving hope.

So you explore political, economic, social, and technological questions for treating Parkinson's, investigating outlooks for commerce. See too how R&D can let companies benefit patients. Discover what the future holds.

You find, then, what stimulates and restrains players in that sector, and affects its results.

Companies and 2018 market value - find prospects for success in PD medicines

What happens next? Our new study predicts the world market for Parkinson's-treating drugs will reach $3461m in 2018. There big pharma and specialty companies can gain, expanding business. Explore how and where.

And there you examine activities of many organisations, including these firms:• Orion Pharmaceuticals• Novartis• Boehringer Ingelheim• GlaxoSmithKline (GSK)• Teva Pharmaceutical Industries.

R&D for treating PD holds advantages, and from 2014 there will arise opportunity. From this decade, patients, payers, and producing companies will benefit.

And you discover how that market can perform, staying ahead in data.

Ways Parkinson's Disease: World Drug Industry and Market 2014-2024 helps you

In particular, our investigation gives you this knowledge:• Revenues there to 2024 at world level, for 5 submarkets, and 3 top products - assess outlooks for production, marketing, and sales• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - examine developed and developing countries for potential revenues• Prospects for established competitors, emerging companies, and new entrants - explore portfolios, results, strategies, successes, and developmental activities.

Information found nowhere else, helping your searches, analyses, and plans

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore the business possibilities.

With our data you're less likely to fall behind in knowledge or miss opportunity for treating that nervous system disease. Being free to choose, you find how you could save time and effort with our study, helping your planning, decisions, and influence.

1. Executive Summary

1.1 Parkinson's Disease Therapy: World Market Overview to 20241.2 Chapter Outlines1.3 Research and Analysis Methods

2. Introduction to Parkinson's Disease and its Treatments

2.1 What Causes Parkinson's?2.2 Motor Symptoms of Parkinson's Disease2.2.1 Tremor: The First Sign of PD2.2.2 Uncontrolled Muscle Contractions Cause Rigidity2.2.3 Bradykinesia: The Most Characteristic Feature of Parkinson's2.2.4 Postural Instability Manifests as PD Progresses2.3 Neuropsychiatric Symptoms are Common in PD Patients2.3.1 Behavioural Deficits are Often the Most Widespread2.3.2 Cognitive Impairment Impede Daily Tasks2.3.3 Autonomic Dysfunction: Another Common Occurrence2.4 Other Symptoms Associated with Parkinson's2.5 Parkinson's Disease: Diagnosis and Treatment2.5.1 Diagnosis is Difficult2.5.2 Treatment Options - Therapeutic Classes

3. Parkinson's Disease: World Drugs Market, 2014-2024

3.1 Sales of the Overall World PD Drugs Market, 2013-20243.2 Parkinson's Disease: Market Segmentation, 20123.3 Overall PD Drug Market: Commercial Drivers and Restraints3.4 Dopaminergic Agents: Foundation of PD Treatment3.4.1 Levodopa Therapy3.4.2 Patent Expiries Affect the Market3.4.3 New Levodopa Therapies on the Horizon3.4.4 Dopaminergic Agents: Market Projections to 20243.5 Dopamine Receptor Agonists: The Leading Class in 20133.5.1 Dopamine Agonists: A Front Line Drug3.5.2 Advantages over L-Dopa Therapy3.5.3 Leading Drugs in the Segment3.5.4 Thin R&D Pipeline in That Segment3.5.5 Dopamine Receptor Agonists: Market Projections, 2014-20243.6 Catechol-O-Methyl Transferase (COMT) Inhibitors: A Popular Choice of Treatment3.6.1 Entacapone: The Leading Drug in this Segment3.6.2 Commercial Scope for COMT Inhibitors3.6.3 COMT Inhibitors: Market Projections, 2014-20243.7 Are Monoamine Oxidase-B (MAO-B) Inhibitors Better Than COMT?3.7.1 MAO-B Inhibitor Therapeutics in the Market3.7.2 New MAO-B Products in Development3.7.3 MAO-B Inhibitors: Market Projections, 2014-20243.7.4 Other Mechanisms of Action: A Growing Opportunity3.7.5 A Broad and Diverse Segment3.7.5.1 Anticholinergics Therapeutics: The Oldest Class of PD Drugs3.7.5.2 Glutamate Antagonists: Not a Popular Choice3.7.6 Other Drugs in the Market3.7.7 The Pipeline Offers Disease Modifying Potential3.7.8 Other Mechanisms of Action: Market Projections, 2014-2024

4. Leading Companies in the PD Drug Market, 2014

4.1 PD: The Most Important Therapy Area for Orion Pharmaceuticals4.1.1 Market Forecast for Comtan/Stalevo, 2014-20244.2 Teva's Azilect Continues to Grow4.2.1 Market Forecast for Azilect, 2014-20244.3 UCB's Leading Neupro Patch Drug4.3.1 Market Forecast for Neupro, 2014-20244.4 Other Market Players

5. The Leading National Markets, 2014-2024

5.1 Regional Breakdown of the World PD Drug Market, 20125.2 The World PD Drug Market: Regional Forecasts to 20245.3 The PD Drug Market in the US: The Largest Single National Market5.3.1 Market Projections for the US, 2014-20245.4 The PD Drug Market in the Five Leading European National Markets (EU5), 2014-20245.4.1 Market Projections for the EU5, 2014-20245.4.2 EU5 Breakdown by Country, 20125.4.3 Market Projection for EU5 Countries, Regional Breakdown5.4.4 Germany: The Largest EU5 Market5.4.4.1 Predictions for the German PD Drug Market, 2014-20245.4.5 France: Strong Healthcare System - What's Possible There?5.4.5.1 Predictions for the French PD Drug Market, 2014-20245.4.6 UK's Spending Restrictions Affect the PD Drugs Market5.4.6.1 Predictions for the UK PD Drug Market, 2014-20245.4.7 Spain - What Effects Will Austerity Have on PD Drug Sales?5.4.7.1 Predictions for the Spanish PD Drug Market, 2014-20245.4.8 The PD Drug Market in Italy: Rising Ageing Population5.4.8.1 Predictions for the Italian PD Drug Market, 2014-20245.5 Japan has the Highest Proportion of Over-65s in the World5.5.1 Predictions for Japanese PD Drug Market, 2014-20245.6 PD Drug Market in Emerging Countries: Brazil, Russia, India and China (BRIC)5.6.1 Breakdown of BRIC Revenues by Country, 20125.6.2 Market Projections for BRIC Nations' PD Drug Sales, 2014-20245.6.3 Brazil's Rapid Growth of the Pharma Market - What's the Future?5.6.4 Russia's Growing Middle-Class Gives Pharma Sales Opportunities5.6.5 India: Generic Manufacturers Seek to Dominate the PD Market5.6.6 China's Ageing Population Stimulates Sales of PD-Treating Medicines

6. Research and Development for Treating Parkinson's Disease

6.1 New Mechanisms of Action in the Late-Stage R&D Pipeline6.2 Growing Potential of Marketed Products: Phase IV Studies6.3 Phase III Clinical Products Promising Potential in the PD market6.3.1 Rytary (Impax Laboratories): The New Generation of Levodopa6.3.1.1 Reformulations of Levodopa: Important Aspect of Therapy6.3.2 Newron's Safinamide Expected Launch in 20146.3.3 Pimavanserin: A First-in-Class Treatment for Parkinson's Disease Psychosis6.3.4 Istradefylline: A Promising A(2a) Receptor Antagonist6.3.5 Termination of Preladenant, A Promising A(2a) Receptor Antagonist6.3.6 Levodopa/Carbidopa Intestinal Gel (LCIG)6.3.7 Can Opicapone Compete with Existing COMT Inhibitors6.3.8 Pitolisant: Addressing an Unmet Need6.3.9 Northera: Oral Precursor of Norepinephrine6.3.10 Targin by Mundipharm6.3.11 Nurelin for Levodopa-Induced Dyskinesia6.3.12 SYN-115: Superior to Istradefylline?6.4 Phase II PD Pipeline: Overview6.4.1 Glutamatergic Drugs: Main Target for Pipeline Candidates6.4.1.1 AFQ056 vs Dipraglurant6.4.2 Fipamezole: Another Promising A(2a) Receptor Antagonist6.4.3 CVT-301: A Novel Intrapulmonary Approach6.4.4 DM-1992: Can Compete with Levodopa Reformulations?6.4.5 The Accordion Pill Carbidopa/Levodopa by Intec Pharma6.4.6 Orient Addresses Sialorrhoea6.4.7 NH004: Formulated with a Muco-Adhesive Property6.4.8 VR040: A Reformulation of Apomorphine6.4.9 AVP-923: A Novel Approach for LID-PD6.4.10 PD Giant Orion, Develop a New Levodopa Drug, ODM-1016.4.11 News for NeuroDerm's Reformulations6.5 Phase I and Pre-clinical PD Pipeline: Overview6.5.1 Vernalis' A(2a) Receptor Antagonist Drug in Phase Ib/IIa6.5.2 Sanofi Collaborates with The Michael J. Fox Foundation6.5.3 UCL Show Exenatide Potential in Parkinson's6.5.4 Titan Pharmaceuticals Develop a Novel Platform6.6 Neuroprotective Drugs Offer Hope6.6.1 Isradipine by The Parkinson Study Group6.6.2 Phytopharm and Cogane Development6.6.3 The Potential of Dietary Supplements6.6.4 GCase Enzymes: Amicus and Biogen Strike A Deal for Parkinson's6.6.5 Research Finds Ursodeoxycholic Acid (UDCA) A Potential Cure for Parkinson's6.6.6 PD Biomarkers: Potential for Revolutionising Diagnosis and Treatment6.6.7 Antibody Targeting: The Coming of Age6.7 Gene Therapy: Promising Research and Technology6.7.1 ProSavin: Leading Gene Therapy Product6.7.2 CERE-120 Promises Repair of Damaged Dopaminergic Neurons6.7.3 AAV-hAADC-2: Another Gene Therapy Contender6.8 Parthenogenesis (International Stem Cell Corporation): A Promising Outlook for PD Technology

7. Qualitative Analysis of the PD Drug Market, 2014

7.1 SWOT Analysis of the PD Market7.1.1 Strengths and Weaknesses in the PD Drug Industry in 20147.1.2 Opportunities and Threats There from 2014 Onwards7.2 STEP Analysis of the PD Market7.2.1 Social Implication of Living with PD7.2.2 Technological Developments on the Horizon7.2.3 Economic Pressures: Healthcare Budgeting7.2.4 Political Issues: Patent Challenges, Data Exclusivity and Regulatory Pathways

8. Research Interviews

8.1 Interview with Dr. Simon Craw, International Stem Cell Corporation, California, US8.1.1 The Overall PD Market8.1.2 Current Understanding of Stem Cell Therapy8.1.3 ISCO's Novel PD Programme8.1.4 The Potential of Immune-Matching8.1.5 The Controversy Surrounding Stem Cell Research8.1.6 The Potential for Parthenogenesis in PD and Other Applications8.2 Interview with Dr Neal Farber, CEO, NeuroHealing Pharmaceuticals, Massachusetts, US8.2.1 Advantages of Anticholinergics over Current Treatment Methods8.2.2 Application of NH004 in Other Neurological Diseases8.2.3 Improving Quality of Life

9. Conclusions from the Research and Analysis

9.1 The World PD Medicines Market: Predictions to 20249.2 Which Drug Class will Dominate the Market in 2024?9.3 Disease Modification: The Ultimate Goal9.4 The Future of the Industry and Market for Parkinson's Medicines

List of Tables

Table 2.1 Overview of the Therapeutic Drug Classes for PD, 2014Table 3.1 World Parkinson's Disease Drug Market, Revenue ($m), AGR (%), CAGR (%), 2013-2018Table 3.2 World Parkinson's Disease Drug Market, Revenue ($m), AGR (%), CAGR (%), 2019-2024Table 3.3 PD Market Segmentation, Revenues ($m), Market Shares (%), 2012Table 3.4 PD Market Breakdown by Segment: Forecasts ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 3.5 PD Market Breakdown by Segment: Forecasts ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 3.6 Formulations of Levodopa Therapy, 2013Table 3.7 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 3.8 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 3.9 Overview of Therapeutic Drug Classes in PD Therapy, 2014Table 3.10 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 3.11 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 3.12 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 3.13 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 3.14 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 3.15 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 3.16 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 3.17 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 4.1 Orion's Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2018Table 4.2 Orion's Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024Table 4.3 Teva's Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2018Table 4.4 Teva's Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024Table 4.5 UCB's Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2018Table 4.6 UCB's Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024Table 5.1 PD Market Breakdown by Region, Revenues ($m), Market Shares (%), 2012Table 5.2 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.3 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.4 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.5 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.6 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.7 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.8 EU5 Regional Breakdown by Country, Revenues ($m), Market Share (%), 2012Table 5.9 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.10 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.11 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.12 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.13 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.14 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.15 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.16 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.17 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.18 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.19 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.20 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.21 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.22 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.23 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.24 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.25 BRIC Regional Breakdown by Country, Revenues ($m), Market Shares (%), 2012Table 5.26 BRIC PD Drug Market Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.27 BRIC PD Drug Market Breakdown Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.28 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.29 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.30 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.31 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.32 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.33 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 5.34 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018Table 5.35 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024Table 6.1 Late-Stage PD Pipeline, 2013Table 6.2 Reformulations of Levodopa and Other Dopaminergic Agents in Development, 2013Table 6.3 Phase II PD Pipeline, 2013Table 6.4 Glutamatergic PD Pipeline, 2013Table 6.5 Early-Stage Developments for PD, 2013Table 6.6 Selected Gene Therapies in the PD Pipeline, 2013Table 7.1 Parkinson's Disease Drug Market: Strengths and Weaknesses, 2014Table 7.2 Parkinson's Disease Drug Market: Opportunities and Threats, 2014-2024Table 7.3 PD Drug Market: STEP Analysis, 2014

List of Figures

Figure 3.1 World PD Drug Market, Revenues ($m), 2012-2024Figure 3.1 World PD Drug Market, Revenues ($m), 2012-2024Figure 3.2 PD Market Segmentation ($m), Market Shares (%), 2012Figure 3.3 PD Drug Market Breakdown by Segment, Revenues ($m), 2013-2024Figure 3.4 PD Drug Market, Drivers and Restraints, 2014-2024Figure 3.5 Dopaminergic Agents Segment Forecast, Revenues ($m), 2013-2024Figure 3.6 Dopaminergic Agents Market: Drivers and Restraints, 2014-2024Figure 3.7 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), 2013-2024Figure 3.8 Dopamine Receptor Agonists Market, Drivers and Restraints, 2014-2024Figure 3.9 COMT Inhibitors Segment Forecast, Revenues ($m), 2013-2024Figure 3.10 COMT Inhibitors Market, Drivers and Restraints, 2014-2024Figure 3.11 MAO Inhibitors Segment Forecast, Revenues ($m), 2013-2024Figure 3.12 MAO Inhibitors Market, Drivers and Restraints, 2014-2024Figure 3.13 Other Mechanisms of Action Segment Forecast, Revenues ($m), 2013-2024Figure 3.14 Other Mechanisms of Action, Market Drivers and Restraints, 2014-2024Figure 4.1 Revenues ($m) of Parkinson's Drugs by Leading Company, 2010-2012Figure 4.2 Orion's Comtan/Stalevo Drug Revenues ($m) Forecast, 2013-2024Figure 4.3 Teva's Azilect Drug Revenues Forecast, 2013-2024Figure 4.4 UCB's Neupro Drug Revenues Forecast, 2013-2024Figure 5.1 PD Market Breakdown by Region, Revenues ($m), Market Shares (%), 2012Figure 5.2 PD Drug Market Breakdown by Region, Revenues ($m), 2013-2024Figure 5.3 US Over-65 Population as Percentage of Overall Population, 2012-2024Figure 5.4 US PD Drug Market, Revenue Forecast ($m), 2013-2024Figure 5.5 EU5 PD Drug Market, Revenue ($m), 2013-2024Figure 5.6 EU5 Regional Breakdown by Country, Revenues ($m), Market Share (%), 2012Figure 5.7 EU5 Regional Breakdown by Country, Revenues ($m), 2013-2024Figure 5.8 Over-65 Population in Germany as Percentage of Overall Population, 2012-2024Figure 5.9 German PD Drug Market, Revenues ($m), 2013-2024Figure 5.10 Over-65 Population in France as Percentage of Overall Population, 2012-2024Figure 5.11 French PD Drug Market, Revenues ($m), 2013-2024Figure 5.12 Over-65 Population in the UK as a Percentage of Overall Population, 2013-2024Figure 5.13 UK PD Drug Market, Revenues ($m), 2013-2024Figure 5.14 Over-65 Population in Spain as Percentage of Overall Population, 2012-2024Figure 5.15 Spanish PD Drug Market, Revenues ($m), 2013-2024Figure 5.16 Over-65 Population in Italy as Percentage of Overall Population, 2012-2024Figure 5.17 Italian PD Drug Market, Revenues ($m), 2013-2024Figure 5.18: Over-65 Population in Japan as Percentage of Overall Population, 2012-2024Figure 5.19 Japanese PD Drug Market, Revenues ($m), 2013-2024Figure 5.20 BRIC PD Drug Market, Revenue ($m), 2012-2024Figure 5.21 BRIC Regional Breakdown by Country, Revenues ($m), Market Share (%), 2012Figure 5.22 BRIC PD Drug Market Breakdown, Revenues ($m), 2013-2024Figure 5.23 Brazilian PD Drug Market, Revenues ($m), 2013-2024Figure 5.24 Russian PD Drug Market, Revenues ($m), 2013-2024Figure 5.25 Indian PD Drug Market, Revenues ($m), 2013-2024Figure 5.26 Chinese PD Drug Market, Revenues ($m), 2013-2024Figure 8.1 Parthenogenesis Results in Cells Inheriting a Duplicate Set of HLA Genes, which Reduces Immune RejectionFigure 9.1 PD Drug Market, Overall Revenues ($m), 2012, 2018 and 2024Figure 9.2 PD Drug Market by Segment, Revenues ($m), 2012, 2018 and 2024

Companies Listed

Abbott LaboratoriesAbbVie PharmaceuticalsAcadia PharmaceuticalsAdamas PharmaceuticalsAddex TherapeuticsAmarantus BioSciencesAmerican Academy of NeurologyAmgenAmicus TherapeuticsAmylin PharmaceuticalsArk TherapeuticsAssogenericiAstraZenecaAvanir PharmaceuticalsAxxonis PharmaBIAL - PortelaBiogen IdecBioprojet PharmaBioSante PharmaceuticalsBiotie TherapiesBiovailBoehringer IngelheimCardiovascular and Renal Drug Advisory CommitteeCeregeneChelsea TherapeuticsCivitas TherapeuticsColumbia UniversityDainippon Sumitomo PharmaDepomedDiaGenicDomain TherapeuticsDr. Reddy's LaboratoriesDuke University, Duke Medical CenterDurin TechnologiesEisaiEuropean Medicines Agency (EMEA/EMA)Food and Drug Administration (US FDA)GenzymeGlaxoSmithKline (GSK)Impax LaboratoriesIntec PharmaInternational Stem Cell Corporation (ISCO)IpsenJuvantia PharmaKyowa Hakko KirinLundbeckMeiji SeikaMerck & Co.Merck SeronoMinistry of Health, Labour and Wealth (MHLW)Mundipharma ResearchMylanNapp PharmaceuticalsNational Health Service (NHS, UK)National Institute for Health and Clinical Excellence (NICE, UK)National Institute of Neurological Disorders and Stroke (NINDS, US)National Institutes of Health (NIH, US)National Parkinson FoundationNeuren PharmaceuticalsNeurodermNeuroGenerationNeuroHealing PharmaceuticalsNeurologixNew Jersey School of Osteopathic Medicine (UMDNJ-SOM)Newron PharmaceuticalsNovartisNuroProOno PharmaceuticalsOrient PharmaOrionOtsuka PharmaceuticalsOxford BioMedicaPar PharmaceuticalsParkinson's UKPfizerPharmaceutical Research and Manufacturers Association (PhRMA)PhytopharmPower3 Medical ProductsProthena CorporationRocheRoxane LaboratoriesSanofiSantheraSchering PloughSheffield Institute for Translational Neuroscience (SITraN)SK BiosciencesSkyepharmaSun PharmaceuticalsTechnion-Israel Institute of TechnologyTeva Pharmaceutical IndustriesThe Michael J. Fox FoundationThe Parkinson Study GroupTitan PharmaceuticalsUCBuniQureUniversity College London (UCL)ValeantVarinelVectura GroupVernalisWatson PharmaceuticalsWockhardtXenoPortYale UniversityZambon Group

To order this report: Parkinson's Disease: World Drug Industry and Market 2014-2024 http://www.reportlinker.com/p02041935/Parkinsons-Disease-World-Drug-Industry-and-Market-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

__________________________


Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Agility is top of mind for Cloud/Service providers and Enterprises alike. Policy Driven Data Center provides a policy model for application deployment by decoupling application needs from the underlying infrastructure primitives. In his session at 15th Cloud Expo, David Klebanov, a Technical Solutions Architect with Cisco Systems, discussed how it differentiates from the software-defined top-down control by offering a declarative approach to allow faster and simpler application deployment. Davi...
In today's digital world, change is the one constant. Disruptive innovations like cloud, mobility, social media, and the Internet of Things have reshaped the market and set new standards in customer expectations. To remain competitive, businesses must tap the potential of emerging technologies and markets through the rapid release of new products and services. However, the rigid and siloed structures of traditional IT platforms and processes are slowing them down – resulting in lengthy delivery ...
Sematext is a globally distributed organization that builds innovative Cloud and On Premises solutions for performance monitoring, alerting and anomaly detection (SPM), log management and analytics (Logsene), and search analytics (SSA). We also provide Search and Big Data consulting services and offer 24/7 production support for Solr and Elasticsearch.
Plutora provides enterprise release management and test environment SaaS solutions to clients in North America, Europe and Asia Pacific. Leading companies across a variety of industries, including financial services, telecommunications, retail, pharmaceutical and media, rely on Plutora's SaaS solutions to orchestrate releases and environments faster and with integrity. Products include Plutora Release Manager, Plutora Test Environment Manager and Plutora Deployment Manager.
Disruptive macro trends in technology are impacting and dramatically changing the "art of the possible" relative to supply chain management practices through the innovative use of IoT, cloud, machine learning and Big Data to enable connected ecosystems of engagement. Enterprise informatics can now move beyond point solutions that merely monitor the past and implement integrated enterprise fabrics that enable end-to-end supply chain visibility to improve customer service delivery and optimize sup...
Over the last few years the healthcare ecosystem has revolved around innovations in Electronic Health Record (HER) based systems. This evolution has helped us achieve much desired interoperability. Now the focus is shifting to other equally important aspects - scalability and performance. While applying cloud computing environments to the EHR systems, a special consideration needs to be given to the cloud enablement of Veterans Health Information Systems and Technology Architecture (VistA), i.e....
WSM International is launching a DevOps services division that offers assessment, consulting and implementation to large enterprises and organizations with complex infrastructures. This is the first independent services company to create a dedicated practice to help organizations looking to transition to the DevOps model. The concept of DevOps is to blend information technology (IT) software development with operations to optimize the computing infrastructure according to the specific needs of ...
WSM International has launched a DevOps services division that offers assessment, consulting and implementation to large enterprises and organizations with complex infrastructures. The concept of DevOps is to blend information technology (IT) software development with operations to optimize the computing infrastructure according to the specific needs of the organization. According to a recent press release from Gartner, "By 2016, DevOps will evolve from a niche strategy employed by large cloud ...
Cloud is not a commodity. And no matter what you call it, computing doesn’t come out of the sky. It comes from physical hardware inside brick and mortar facilities connected by hundreds of miles of networking cable. And no two clouds are built the same way. SoftLayer gives you the highest performing cloud infrastructure available. One platform that takes data centers around the world that are full of the widest range of cloud computing options, and then integrates and automates everything. J...
With the arrival of the Big Data revolution, a data professional is expected to master a broad spectrum of complex domains including data processing, mathematics, programming languages, machine learning techniques, and business knowledge. While this mastery is undoubtedly important, this narrow focus on tool usage has divorced many from the imagination required to solve real-world problems. As the demand for analysis increases, the data science community must transform from tool experts to "data...
SYS-CON Media announced today that 9 out of 10 " most read" DevOps articles are published by @DevOpsSummit Blog. Launched in October 2014, @DevOpsSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dy...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading in...
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, shared some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, de...
The Internet of Things (IoT) promises to evolve the way the world does business; however, understanding how to apply it to your company can be a mystery. Most people struggle with understanding the potential business uses or tend to get caught up in the technology, resulting in solutions that fail to meet even minimum business goals. In his session at @ThingsExpo, Jesse Shiah, CEO / President / Co-Founder of AgilePoint Inc., showed what is needed to leverage the IoT to transform your business. ...
15th Cloud Expo, which took place Nov. 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, expanded the conference content of @ThingsExpo, Big Data Expo, and DevOps Summit to include two developer events. IBM held a Bluemix Developer Playground on November 5 and ElasticBox held a Hackathon on November 6. Both events took place on the expo floor. The Bluemix Developer Playground, for developers of all levels, highlighted the ease of use of Bluemix, its services and functionalit...